No headlines found.
Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference
Globe Newswire (Mon, 31-Mar 8:30 AM ET)
Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress
Globe Newswire (Thu, 13-Feb 6:30 AM ET)
Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025
Globe Newswire (Thu, 6-Feb 8:30 AM ET)
Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Globe Newswire (Tue, 4-Feb 8:30 AM ET)
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.
Veru trades on the NASDAQ stock market under the symbol VERU.
As of April 9, 2025, VERU stock price climbed to $0.54 with 1,221,991 million shares trading.
VERU has a beta of 0.36, meaning it tends to be less sensitive to market movements. VERU has a correlation of 0.00 to the broad based SPY ETF.
VERU has a market cap of $79.14 million. This is considered a Micro Cap stock.
Last quarter Veru reported $0 in Revenue and -$.07 earnings per share. This fell short of revenue expectation by $-3 million and exceeded earnings estimates by $.01.
In the last 3 years, VERU traded as high as $24.55 and as low as $.36.
The top ETF exchange traded funds that VERU belongs to (by Net Assets): IWM, VTI, VXF, IWO, VTWO.
VERU has underperformed the market in the last year with a return of -47.5%, while the SPY ETF gained +7.1%. In the last 3 month period, VERU fell short of the market, returning -25.5%, while SPY returned -6.6%. However, in the most recent 2 weeks VERU has outperformed the stock market by returning +4.5%, while SPY returned -4.7%.
VERU support price is $.47 and resistance is $.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VERU shares will trade within this expected range on the day.